Sorrento Therapeutics, Inc.
4955 Directors Pl.
San Diego
California
92121
United States
Website: http://sorrentotherapeutics.com/
About Sorrento Therapeutics, Inc.
382 articles about Sorrento Therapeutics, Inc.
-
Sorrento Therapeutics, Inc. The Unexpected Death Of Its Chief Business Officer
8/1/2014
-
Sorrento Therapeutics, Inc. Awarded Grant From The National Institutes Of Health For The Development Of A Small Molecule Myc Inhibitor
7/21/2014
-
Sorrento Therapeutics, Inc. Awarded Grant From The National Institutes of Health (NIH) For The Development Of A Small Molecule Myc Inhibitor
7/21/2014
-
Sorrento Therapeutics, Inc. Awarded Up To $2.6 Million From The National Institutes of Health (NIH) For The Development Of New Anti-Bacterial Bispecific Antibodies And Antibody Formulated Drug Conjugates
7/1/2014
-
Morphotek Inc. And Sorrento Therapeutics, Inc. Sign An Exclusive Research And Option Agreement To Generate And Develop Morphotek Antibody Drug Conjugates
6/25/2014
-
Sorrento Therapeutics, Inc. To Present At Biotechnology Industry Organization (BIO) Business Forum
6/23/2014
-
Sorrento Therapeutics, Inc. Announces Confidential Submission Of Draft Registration Statement For Initial Public Offering (IPO) Of Its Wholly-Owned Subsidiary Ark Animal Health With The SEC
6/23/2014
-
Sorrento Therapeutics, Inc. Announces Underwriters' Exercise Of Over-Allotment Option
6/13/2014
-
Sorrento Therapeutics, Inc. To Present At Jefferies and Co. 2014 Global Healthcare Conference
6/2/2014
-
Sorrento Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock
5/15/2014
-
Sorrento Therapeutics, Inc. Announces Transfer Of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin From National Institutes of Health (NIH)
5/13/2014
-
Oxford Finance And Silicon Valley Bank Expand Existing Senior Credit Facility With Sorrento Therapeutics, Inc. To $12.5 Million
4/17/2014
-
Sorrento Therapeutics, Inc. Appoints Ian Walters As Senior Vice President Of Translational Medicine And Corporate Development
4/8/2014
-
Sorrento Therapeutics, Inc. Announces Presentation Of Data From Clinical Study Of Resiniferatoxin For Intractable Cancer Pain At ASRA Meeting
4/4/2014
-
Sorrento Therapeutics, Inc. Announces Key Presentation On Cynviloq At The American Association for Cancer Research Annual Meeting
4/4/2014
-
Sorrento Therapeutics, Inc. Appoints Mark Durand To Its Board Of Directors
3/11/2014
-
Sorrento Therapeutics, Inc. To Present At ROTH Capital Partners 26th Annual Growth Stock Conference
3/6/2014
-
Sorrento Therapeutics, Inc. Announces Three Presentations And A Satellite Symposium On Cynviloq™ At The 31st Annual Miami Breast Cancer Conference
3/6/2014
-
Sorrento Therapeutics, Inc. Hires Mike Royal As Senior Vice President Of Clinical Development
3/3/2014
-
Sorrento Therapeutics, Inc. Expands Its Exclusive Rights To Cynviloq To Include Australia, Canada And Mexico
2/10/2014